Cancer: Improving immunotherapy: Revisiting the immunologist's little secret

Science Translational Medicine

Volumn 4, Issue 120, 2012, Pages

  Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; FLAGELLIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; APOPTOSIS REGULATORY PROTEIN; BIRC1E PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; IPAF PROTEIN, MOUSE; NEURONAL APOPTOSIS INHIBITORY PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; ENZYME ACTIVATION; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; ANIMAL; FEMALE; IMMUNOLOGY; MALE; METABOLISM; NEOPLASM; NOTE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CANCER VACCINES; FEMALE; MALE; NEOPLASMS; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; TOLL-LIKE RECEPTORS;

EID: 84856977660     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003658     Document Type: Short Survey

References (13)

1. J. Garaude, A. Kent, N. van Rooijen, J. M. Blander, Simultaneous targeting of Toll- and Nod-like receptors induces eff ective tumor-specific immune responses. Sci. Transl. Med. 4, 120ra16 (2012).
2. C. A. Janeway Jr., Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13 (1989).
3. C. A. Janeway Jr., R. Medzhitov, Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
4. P. Matzinger, The danger model: A renewed sense of self. Science 296, 301-305 (2002).
5. L. A. O'Neill, The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226, 10-18 (2008).
6. F. Martinon, A. Mayor, J. Tschopp, The infl ammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
7. G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, A. Lanzavecchia, Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769-776 (2005).
8. Q. Zhu, C. Egelston, S. Gagnon, Y. Sui, I. M. Belyakov, D. M. Klinman, J. A. Berzofsky, Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120, 607-616 (2010).
9. M. Kwissa, S. P. Kasturi, B. Pulendran, The science of adjuvants. Expert Rev. Vaccines 6, 673-684 (2007).
10. J. A. Berzofsky, J. D. Ahlers, I. M. Belyakov, Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1, 209-219 (2001).
11. J. M. Blander, R. Medzhitov, Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808-812 (2006).
12. S. Burgdorf, C. Schölz, A. Kautz, R. Tampé, C. Kurts, Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 9, 558-566 (2008).
13. F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, J. L. Perfettini, F. Schlemmer, E. Tasdemir, M. Uhl, P. Génin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. André, R. Lidereau, N. M. McLaughlin, N. M. Haynes, M. J. Smyth, G. Kroemer, L. Zitvogel, Activation of the NLRP3 infl ammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).